Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Multiple Myeloma
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Phase III, multi-centre, randomised, parallel group trialMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: Randomisation 1 is open label Randomisation 2 is double-blind, placebo-controlledPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03720041
- Collaborators
- Cancer Research UK
- Takeda
- Celgene
- Investigators
- Principal Investigator: Gordon Cook, MD University of Leeds Principal Investigator: Graham Jackson, MD Freeman Hospital, Newcastle-Upon-Tyne